Promising cancer combo trial halted early – no clear answers yet
NCT ID NCT05061420
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a new drug called SAR444245 combined with either pembrolizumab or cetuximab in 59 adults with head and neck cancer that had spread or come back. The goal was to see if the combinations could shrink tumors. However, the study was terminated early, so we don't have enough information to know if the treatments work or are safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR444245 (THOR-707) combined with pembrolizumab or cetuximab
What this could lead to
If it had worked, this could have pointed toward a new treatment option for head and neck cancer that doesn't respond to standard therapy.
What could go wrong
The study was terminated early, so we don't have enough data to know if the combination is effective or safe. Early-phase trials often fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope- Site Number : 8400007
Duarte, California, 91010, United States
-
Investigational Site Number : 0320001
Buenos Aires, 1012, Argentina
-
Investigational Site Number : 1240001
Montreal, Quebec, H4A 3J1, Canada
-
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, 8420383, Chile
-
Investigational Site Number : 1520002
Temuco, 4800827, Chile
-
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, 7500921, Chile
-
Investigational Site Number : 1520004
Viña del Mar, Valparaiso, 2540488, Chile
-
Investigational Site Number : 1580003
Tainan, 704, Taiwan
-
Investigational Site Number : 2500001
Villejuif, 94800, France
-
Investigational Site Number : 2500002
Strasbourg, 67033, France
-
Investigational Site Number : 2500003
Bordeaux, 33075, France
-
Investigational Site Number : 2500006
Paris, 75015, France
-
Investigational Site Number : 2500008
Lyon, 69008, France
-
Investigational Site Number : 2760004
Berlin, 12200, Germany
-
Investigational Site Number : 3800003
Brescia, 25123, Italy
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 05505, South Korea
-
Investigational Site Number : 5280001
Nijmegen, 6500 HB, Netherlands
-
Investigational Site Number : 5280002
Amsterdam, 1066, Netherlands
-
Investigational Site Number : 7240001
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7240003
Madrid, Madrid, Comunidad de, 28046, Spain
-
Investigational Site Number : 7240004
Barcelona, Barcelona [Barcelona], 08036, Spain
-
Investigational Site Number : 7240005
Madrid, Madrid, Comunidad de, 28040, Spain
-
Seattle Cancer Care Alliance Site Number : 8400006
Seattle, Washington, 98115, United States
-
Thomas Jefferson University Hospital Site Number : 8400003
Philadelphia, Pennsylvania, 19107, United States
-
University of Colorado- Site Number : 8400004
Aurora, Colorado, 80045, United States
-
University of Michigan- Site Number : 8400008
Ann Arbor, Michigan, 48109, United States